Join this webinar to explore how leading organizations are expanding their understanding and approaches to broadening data types to enable innovation.
Join Abby McDonell, Sr. Program Manager with IQVIA’s Clinical Trial Transparency Team (powered by Privacy Analytics), to gain actionable insights on optimising your medical writing processes to ...
On May 16, the European Medicines Agency (EMA) confirmed that after a long hiatus (punctuated only by COVID-related publications), Policy 0070 will officially resume in September 2023. Join Niamh ...
As a clinical trial sponsor, you’re under tight timelines to balance participant privacy and data utility in clinical document submissions while justifying and protecting commercially sensitive ...
As a clinical trial sponsor, you’re under pressure to be transparent, but how do you ensure your clinical study documents don’t reveal confidential trade secrets when published by regulators?
As a clinical trial sponsor, you were already facing tight timelines and resource constraints in handling regulatory requirements for document anonymization and redaction.
In this panel replay, you’ll get tangible strategies and tactics to identify, substantiate and communicate a compelling, urgent reason to provide internal access to sensitive data or to share ...
CDOs are increasingly becoming responsible for enterprise-wide governance and the use of information as an asset, as well as organizational data sharing & analytics strategy.
Are you confident in the technology you’re using to protect the privacy of people represented in the sensitive data your organization handles every day?
Data and transparency leaders in the pharma industry are increasingly embracing the digital shift toward reusing clinical trial data for new benefits, including future trial design. Watch our webinar ...
Your organization’s sensitive data is powerful. But failing to use it safely – or failing to use it at all – can lead to reputational damage and loss of trust. When leveraging data derived from ...
Data privacy, handled responsibly, is your unshakable bedrock for earning trust. That earned trust will allow you to innovate in ways that can benefit everyone.
Watch our keynote presentation with Gabriel Eichler, VP and Head of Data for the data42 program at Novartis to help you build trusted data strategies for innovation that benefits everyone.
In this choose your own data sharing adventure, leaders were asked to navigate and overcome several twists and turns – in real time – to meet business needs, while balancing internal resistance to ...
Watch this on-demand executive roundtable presented by MIT Chief Data Officer & Information Quality program and Privacy Analytics – featuring a dynamic discussion about safely sharing sensitive ...
Your organization’s sensitive data is a powerful and valuable resource. But using it in a way that fails to protect individual privacy under regulations such as GDPR, HIPAA, and CCPA can lead to ...
What are anonymization and de-identification? Do they mean the same thing? Is there even consensus about their meaning? Luk Arbuckle draws on his deep experience in anonymization to address these ...
Strategy development can hold you back. You want to leverage your organization’s data assets, including those containing sensitive information, but you can’t get consensus on how to…
In this session, we’ll discuss three emergent trends destined to have a major impact on your transparency planning for 2021.
As the healthcare industry evolves into an ecosystem of data-rich, digitally enabled stakeholders, drug manufacturers are losing their informational advantage in the value chain.
Once a drug company has clinical trial transparency (CTT) capabilities in place, new opportunities to drive value further along the drug development life cycle also emerge.
While structured data is now commonly deidentified and used for a multitude of purposes, it’s only part of the story.
How can companies leverage the increasing business value of the sensitive data they manage (without running afoul of statutory regulations, or stakeholder trust)?
This is a co-presentation by global authorities in data and privacy, ending with a thorough, facilitated Q&A session. In the presentation, our experts share specific data privacy strategies and ...
Before CDOs can unlock data value, they must first understand data potential. Although many CDOs today are deep into analytics, it can be challenging to determine which data assets hold the most ...
Four data analytics and privacy leaders share the story of their respective journeys to either safely turn personal data into business value or earn trust by protecting the privacy of the people ...
California’s Consumer Privacy Act inspired Comcast to evolve the way in which the company protects the privacy of customers who consent to share personal information with them. Doina Iepuras, Senior ...
In this presentation Vivli and Privacy Analytics discuss on how both organizations help data contributors share their data securely while protecting patients’ privacy. The webinar explores the ...
Luk Arbuckle, Chief Methodologist at Privacy Analytics, headquartered in Ottawa, Canada presents extracts from the new white paper: The Five Safes of Risk-Based Anonymization, co-authored with ...
Data velocity and privacy concerns are colliding. Data lakes are turning into data swamps. View our webcast with world-renowned data gurus Jules Polonetsky and Luk Arbuckle.
What is Vivli? Why is it a breakthrough for clinical trials data sharing? In this Executive Conversation, Our Special Guest, Vivli Executive Director Dr. Rebecca Li; and Dr. Khaled El Emam, Founder ...
In this webinar, global data privacy expert Dr. Ann Cavoukian; and Luk Arbuckle, Chief Methodologist, Privacy Analytics Inc.; examine the controversies and challenges that compel organizations to ...
Filter by Data Type
Categories
